173 related articles for article (PubMed ID: 35000397)
1. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia.
Hernández Martínez A; Navajas Hernández P; Martín Rodríguez MDM; Lázaro Sáez M; Olmedo Martín R; Núñez Ortiz A; Argüelles Arias F; Fernández Cano MC; Gallardo Sánchez F; Marín Pedrosa S; González García J; Vázquez Morón JM
Rev Esp Enferm Dig; 2022 Sep; 114(9):516-521. PubMed ID: 35000397
[TBL] [Abstract][Full Text] [Related]
2. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
[TBL] [Abstract][Full Text] [Related]
3. Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.
Carvalhas Gabrielli AM; Ferretti F; Monico CM; Tombetti E; Maconi G; Romeo S; Piazza O Sed N; Caprioli F; Mazzola AM; Alicante S; Bertè R; Lolli E; Scribano ML; Buscarini E; Ricci C; Carmagnola S; Ardizzone S; Cannatelli R
Dig Dis Sci; 2024 May; 69(5):1785-1792. PubMed ID: 38530500
[TBL] [Abstract][Full Text] [Related]
4. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
5. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
6. Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study.
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD
Therap Adv Gastroenterol; 2023; 16():17562848231154103. PubMed ID: 36950251
[TBL] [Abstract][Full Text] [Related]
7. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombia: Real world experience.
Parra-Izquierdo V; Frías-Ordoñez JS; Márquez JR; Juliao-Baños F; Galindo P; Cuadros C; Rojas C; Rojas N; Ardila O; Tovar-Fierro G; García-Duperly R; Vargas M; Flórez-Sarmiento C
Gastroenterol Hepatol; 2023; 46(7):512-521. PubMed ID: 36372256
[TBL] [Abstract][Full Text] [Related]
9. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open.
Sands BE; Armuzzi A; Marshall JK; Lindsay JO; Sandborn WJ; Danese S; Panés J; Bressler B; Colombel JF; Lawendy N; Maller E; Zhang H; Chan G; Salese L; Tsilkos K; Marren A; Su C
Aliment Pharmacol Ther; 2020 Jan; 51(2):271-280. PubMed ID: 31660640
[TBL] [Abstract][Full Text] [Related]
11. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Colombel JF; Osterman MT; Thorpe AJ; Salese L; Nduaka CI; Zhang H; Lawendy N; Friedman GS; Quirk D; Su C; Reinisch W
Clin Gastroenterol Hepatol; 2022 Jan; 20(1):116-125.e5. PubMed ID: 33039585
[TBL] [Abstract][Full Text] [Related]
13. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry.
Chaparro M; Garre A; Mesonero F; Rodríguez C; Barreiro-de Acosta M; Martínez-Cadilla J; Arroyo MT; Manceñido N; Sierra-Ausín M; Vera-Mendoza I; Casanova MJ; Nos P; González-Muñoza C; Martínez T; Boscá-Watts M; Calafat M; Busquets D; Girona E; Llaó J; Martín-Arranz MD; Piqueras M; Ramos L; Surís G; Bermejo F; Carbajo AY; Casas-Deza D; Fernández-Clotet A; García MJ; Ginard D; Gutiérrez-Casbas A; Hernández L; Lucendo AJ; Márquez L; Merino-Ochoa O; Rancel FJ; Taxonera C; López Sanromán A; Rubio S; Domènech E; Gisbert JP
J Crohns Colitis; 2021 Jan; 15(1):35-42. PubMed ID: 32969471
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
[TBL] [Abstract][Full Text] [Related]
16. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
Straatmijer T; van Gennep S; Duijvestein M; Ponsioen CIJ; Gecse KB; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2021 Oct; 33(10):1288-1297. PubMed ID: 33405424
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Quirk D; Wang W; Nduaka CI; Mukherjee A; Su C; Sands BE
Clin Gastroenterol Hepatol; 2022 Aug; 20(8):1821-1830.e3. PubMed ID: 33127596
[TBL] [Abstract][Full Text] [Related]
18. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
Parra-Izquierdo V; Frías-Ordoñez JS; Cuadros C; Vargas M; Vera Chamorro JF; Romero Sanchez C; Flórez-Sarmiento C
Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832
[TBL] [Abstract][Full Text] [Related]
19. Real-World Experience With Tofacitinib Dose De-Escalation in Patients With Moderate and Severe Ulcerative Colitis.
Yu A; Ha NB; Shi B; Cheng YW; Mahadevan U; Beck KR
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3115-3124.e3. PubMed ID: 37187323
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Tofacitinib for Treatment of Moderate to Severe Active Ulcerative Colitis: First Report from Iran.
Jameshorani M; Vahedi H; Sadeghi A; Sima AR; Anushiravani A; Nateghi Beige H; Malekzadeh MM; Naserinejad S; Alatab S
Arch Iran Med; 2021 May; 24(5):354-363. PubMed ID: 34196200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
